Private: Gallery Post #1

17

Feb2016
Ontario has released the February 2016 Summary of Changes document, which includes the addition of Hospira’s Inflectra at a price of $525.00. Please see page 4 of the Summary of Changes document for more information regarding the clinical criteria and listing status of Inflectra.

17

Feb2016

Alexion pCPA Negotiation

Suzanne McGurn, the Executive Officer of the Ontario Public Drug Programs, issued a statement on behalf of the Pan Canadian Pharmaceutical Alliance (pCPA), on February 16, 2016 detailing the end of negotiations with manufacturer Alexion for the listing of Soliris. Please see the following article for more information.

12

Feb2016
The Alberta Price Confirmation (APC) is issued prior to an Alberta Drug Benefit List (ADBL) publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.   ADBL Effective Date APC Tentative Issue Date March 1, 2016 February 2, 2016 April 1, 2016 February 18, ... Read More

12

Feb2016
As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014. Through this newly named report series, the PMPRB monitors and reports on: the latest developments in generic drug pricing and markets ... Read More

12

Feb2016
Since Québec is now participating in the pan-Canadian Pharmaceutical Alliance (pCPA), INESSS recently communicated that information sharing has now become necessary to ensure greater efficiency when conducting drug reviews. As of February 15, 2016, a supplementary document, supporting authorization of information sharing with pCPA, must accompany any drug submission application pertaining ... Read More

02

Feb2016
In November 2015, CADTH received stakeholder feedback on proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process. Feedback was received from three clinicians, three patient advocacy groups, three pharmaceutical companies, and two industry association groups. This stakeholder feedback ... Read More

18

Jan2016
The objective of this preliminary report is to summarize PDCI’s assessment of the national pharmacare cost estimate study (Morgan et al) and identify some alternative mechanisms by which drug coverage in Canada can fulfill the spirit of the Canada Health Act plus the objectives of equity and sustainability.  The final ... Read More

21

Dec2015
The Patented Medicines Prices Review Board (PMPRB) has released their highly anticipated Strategic Plan 2015-2018. The PMPRB’s three-year strategic plan includes four new strategic objectives, a reinvigorated mission statement, and a vision as to how the organization can work with partners and stakeholders in advancing the common goal of ... Read More

14

Dec2015
The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, has released the Annual Report for the year ended December 31, 2014. This year, the format has been updated, adopting a more user-friendly design highlighting the PMPRB activities and emphasizing important trends. Below ... Read More

14

Dec2015
CADTH is currently updating the third edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. To help with this initiative, CADTH is inviting interested stakeholders to provide input. These guidelines detail best practices for conducting economic evaluations and are used to standardize and facilitate economic evaluations while ... Read More